Around 300 drugs exempt from regular price cut under new Japanese provisions
This article was originally published in Scrip
Executive Summary
Around 300 products will escape a reduction in the next regular revision of reimbursement prices for prescription drugs in Japan on April 1st because they meet certain criteria under complex new rules being adopted on a trial basis this year.